Details for Patent: 5,830,882
✉ Email this page to a colleague
Title: | Compositions containing a form of hyaluronic acid and a medicinal agent for treating acne in mammals and methods for administration of such composition |
Abstract: | A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated. |
Inventor(s): | Falk; Rudolf Edgar (Toronto, CA), Asculai; Samuel S. (Toronto, CA) |
Assignee: | Hyal Pharmaceutical Corporation (Mississauga, CA) |
Filing Date: | Jun 05, 1995 |
Application Number: | 08/462,615 |
Claims: | 1. A method of treating acne in a patient in need thereof comprising topically administering to skin affected with acne, a composition comprising a therapeutically effective amount of a drug useful for treating acne, and 10 mg to 1000 mg of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and a pharmaceutically acceptable salt thereof, wherein the form of hyaluronic acid has a molecular weight less than 750,000 daltons but greater than 150,000 daltons. 2. The method of claim 1 wherein the drug useful for treating acne is selected from the group consisting of antibiotics, antibacterials, antimicrobials, and combinations thereof, optionally together with ascorbic acid. 3. The method of claim 2 wherein the form of hyaluronic acid is sodium hyaluronate in an amount between 10 mg and 1000 mg. 4. A pharmaceutical composition for targeting a drug selected from the group consisting of antibiotics, antibacterials, and antimicrobials to a site of underperfused or pathological tissue in a patient, comprising (a) a therapeutically effective dosage amount of the drug, and (b) a form of hyaluronic acid selected from the group consisting of hyaluronic acid and a pharmaceutically acceptable salt thereof, wherein the form of hyaluronic acid has a molecular weight less than 750,000 daltons but greater than 150,000 daltons, and wherein the composition provides 10 mg to 1000 mg of the form of hyaluronic acid per said dosage amount. 5. The composition of claim 4 wherein the composition provides 200 mg to 1000 mg of sodium hyaluronate. 6. The composition of claim 4 wherein the composition further comprises ascorbic acid. |